Quote this publication Share Print

LONSURF (trifluridine/tipiracil), pyrimidine analogue

ONCOLOGY - New medicinal product
Opinions on drugs - Posted on Aug 28 2017

Reason for request

Inclusion

No clinical added value in the treatment of metastatic colorectal cancer

 

  • LONSURF, administered orally, has a marketing authorisation in the treatment of metastatic colorectal cancer (mCRC) patients previously treated with available treatments including chemotherapies based on fluoropyrimidine, oxaliplatin and irinotecan, anti-VEGF agents and anti-EGFR agents, or in cases of noneligibility for these treatments.
  • Its effect is modest on overall survival and progression-free survival at the price of haematological toxicity mainly.
  • There are no data on quality of life based on a validated scale.

 

 

 

 


Actual benefit

Faible

-

Insuffisant


Improvement in actual benefit

V (absence)

-


Contact Us

Évaluation des médicaments